Tumor Necrosis Factor Inhibitor Drugs Market Size, Share & Trends Analysis Report By Product (Humira, Enbrel, Remicade, Simponi, Cimzia), By Application, By Sales Channel, By Region, And Segment Forecasts, 2019 - 2026

Published: Jul, 2019 | Pages: 100 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global tumor necrosis factor inhibitor drugs market size is anticipated to reach USD 42.1 billion by 2026, according to a report published by Grand View Research, Inc. Increasing prevalence of autoimmune diseases, rapid technological advancements, and rise in healthcare expenditure across the globe are some of the major factors expected to drive the growth.

Currently, there are five approved TNF inhibitor drugs in the market- Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab), and Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade have been launched, causing a significant paradigm shift in the market.

The wave of biosimilars pose a significant internal threat to the biologics sale as biosimilars have a comparable efficiency as the original products. The cost-effectiveness of biosimilars makes them an attractive choice in economically sensitive areas. In addition, emerging countries, such as India, China, and South Korea are active participants in the biosimilar market.

Some of the key therapeutic areas involving treatment with TNF inhibitor drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Although these medicines are mostly used for the treatment of autoimmune diseases, several ongoing studies are investigating the role of TNF inhibitors in the treatment of cancer and other inflammatory conditions.

Some of the key players in the TNF inhibitor space are involved in strategic initiatives, such as mergers and acquisitions and joint ventures for the co-development of products. In addition, patent infringement issues between the manufacturers makes the market dynamics intensely competitive. For instance, AbbVie resolved an issue with Boehringer Ingelheim, regarding Humira's intellectual property (IP) rights. As per the terms of the agreement, Boehringer Ingelheim received a non-exclusive license to Humira's IP in the U.S.- scheduled to begin in July 2023.

Further key findings from the study suggest:

• Humira accounted for nearly half the revenue share of TNF inhibitor drugs market in 2018

• Emergence of biosimilars is anticipated to be the major growth rendering driver for the market

• Psoriasis is projected to be the most rapidly growing application segment over the forecast period

• Increased adoption of e-commerce is a key driver for online pharmacies

• TNF inhibitors faces an external threat from IL-inhibitors

 Table of Contents

Chapter 1 Methodology and Scope
                 1.1 Market Segmentation and Scope
                     1.1.1 Segment scope
                     1.1.2 Regional scope
                     1.1.3 Estimates and forecast timeline
                 1.2 Research Methodology
                 1.3 Information Procurement
                     1.3.1 Purchased database:
                     1.3.2 GVR's internal database
                     1.3.3 Secondary sources
                     1.3.4 Primary research
                     1.3.5 Details of primary research
                         1.3.5.1 Data for primary interviews in North america
                         1.3.5.2 Data for primary interviews in Europe
                         1.3.5.3 Data for primary interviews in Asia Pacific
                         1.3.5.4 Data for primary interviews in Middle East and Africa
                 1.4 Information or Data Analysis
                     1.4.1 Data analysis models
                 1.5 Market Formulation & Validation
                 1.6 Model Details
                     1.6.1 Commodity Flow Analysis (Model 1)
                         1.6.1.1 Approach 1: Commodity Flow Approach
                     1.6.2 Volume price analysis (Model 2)
                         1.6.2.1 Approach 2: Volume price analysis
                 1.7 List of Secondary Sources
                 1.8 List of Abbreviations
                 1.9 Objectives
                     1.9.1 Objective 1
                     1.9.2 Objective 2
                     1.9.3 Objective 3
                     1.9.4 Objective 4
Chapter 2 Executive Summary
                 2.1 Market Outlook
                 2.2 Segment Outlook
                 2.3 Competitive Insights
Chapter 3 TNF Inhibitor Drugs Market Variables, Trends & Scope
                 3.1 Disease Primer and Epidemiology
                 3.2 Market Lineage Outlook
                     3.2.1 Ancillary market outlook
                 3.3 Penetration & Growth Prospect Mapping
                 3.4 Product Pipeline Analysis, by Stage
                 3.5 User Perspective Analysis
                     3.5.1 Consumer Behavior Analysis
                 3.6 Regulatory Framework
                 3.7 Market Dynamics
                     3.7.1 Market drivers analysis
                         3.7.1.1 Emergence of biosimilars
                         3.7.1.2 Strong product pipeline
                         3.7.1.3 New product lauches
                         3.7.1.4 Increasing disease prevalence
                         3.7.1.5 Proactive government initiatives
                     3.7.2 Market restraints analysis
                         3.7.2.1 Stringent regulatory approval
                         3.7.2.2 High cost of treatment
                         3.7.2.3 Adverse effect of drugs
                 3.8 TNF Inhibitor Drugs: Market Analysis Tools
                     3.8.1 Industry analysis - Porter's
                     3.8.2 PESTLE analysis
                     3.8.3 Major deals and strategic alliances
                         3.8.3.1 New Product Launch
                         3.8.3.2 Acquisition
                         3.8.3.3 Expansion
                         3.8.3.4 Partnerships
                         3.8.3.5 Marketing & Promotions
Chapter 4 TNF Inhibitor Drugs Market: Segment Analysis, By Product, 2014 - 2026 (USD Million)
                 4.1 Definition and Scope
                 4.2 Product Market Share Analysis, 2018 & 2026
                 4.3 Segment Dashboard
                 4.4 Global TNF Inhibitor Drugs Market, by Product, 2014 to 2026
                 4.5 Market Size & Forecasts and Trend Analyses, 2014 to 2026
                     4.5.1 Humira
                         4.5.1.1 Humira market, 2014 - 2026 (USD Million)
                     4.5.2 Enbrel
                         4.5.2.1 Enbrel market, 2014 - 2026 (USD Million)
                     4.5.3 Remicade
                         4.5.3.1 Remicade market, 2014 - 2026 (USD Million)
                     4.5.4 Simponi/Simponi Aria
                         4.5.4.1 Simponi/Simponi Aria market, 2014 - 2026 (USD Million)
                     4.5.5 Cimzia
                         4.5.5.1 Cimzia market, 2014 - 2026 (USD Million)
                     4.5.6 Biosimilars
                         4.5.6.1 Biosimilars market, 2014 - 2026 (USD Million)
Chapter 5 TNF Inhibitor Drugs Market: Segment Analysis, By Application, 2014 - 2026 (USD Million)
                 5.1 Definition and Scope
                 5.2 Application Market Share Analysis, 2018 & 2026
                 5.3 Segment Dashboard
                 5.4 Global TNF Inhibitor Drugs Market, by Application, 2014 to 2026
                 5.5 Market Size & Forecasts and Trend Analyses, 2014 to 2026
                     5.5.1 Rheumatoid arthritis
                         5.5.1.1 Rheumatoid arthritis market, 2014 - 2026 (USD Million)
                     5.5.2 Psoriasis
                         5.5.2.1 Psoriasis market, 2014 - 2026 (USD Million)
                     5.5.3 Psoriatic arthritis
                         5.5.3.1 Psoriatic arthritis market, 2014 - 2026 (USD Million)
                     5.5.4 Crohn's Disease
                         5.5.4.1 Crohn's disease market, 2014 - 2026 (USD Million)
                     5.5.5 Ulcerative colitis
                         5.5.5.1 Ulcerative colitis market, 2014 - 2026 (USD Million)
                     5.5.6 Ankylosing Spondylitis
                         5.5.6.1 Ankylosing spondylitis market, 2014 - 2026 (USD Million)
                     5.5.7 Juvenile idiopathic arthritis
                         5.5.7.1 Juvenile idiopathic arthritis market, 2014 - 2026 (USD Million)
                     5.5.8 Hidradenitis suppurativa
                         5.5.8.1 Hidradenitis suppurativa market, 2014 - 2026 (USD Million)
                     5.5.9 Others
                         5.5.9.1 Others market, 2014 - 2026 (USD Million)
Chapter 6 TNF Inhibitor Drugs Market: Segment Analysis, By Sales Channel, 2014 - 2026 (USD Million)
                 6.1 Definition and Scope
                 6.2 Sales Channel Market Share Analysis, 2018 & 2026
                 6.3 Segment Dashboard
                 6.4 Global TNF Inhibitor Drugs Market, by Sales Channel, 2014 to 2026
                 6.5 Market Size & Forecasts and Trend Analyses, 2014 to 2026
                     6.5.1 Hospital pharmacy
                         6.5.1.1 Hospital pharmacy market, 2014 - 2026 (USD Million)
                     6.5.2 Specialty pharmacy
                         6.5.2.1 Specialty pharmacy, 2014 - 2026 (USD Million)
                     6.5.3 Online pharmacy
                         6.5.3.1 Online pharmacy market, 2014 - 2026 (USD Million)
Chapter 7 TNF Inhibitor Drugs Market: Regional Market Analysis, 2014 - 2026 (USD Million)
                 7.1 Definition & Scope
                 7.2 Regional Market Share Analysis, 2018 & 2026
                 7.3 Regional Market Dashboard
                 7.4 Regional Market Snapshot
                 7.5 Regional Market Share and Leading Players, 2018
                     7.5.1 North America
                     7.5.2 Europe
                     7.5.3 Asia Pacific
                     7.5.4 Latin America
                     7.5.5 Middle East and Africa
                 7.6 SWOT Analysis
                     7.6.1 North America
                     7.6.2 Europe
                     7.6.3 Asia Pacific
                     7.6.4 Latin America
                     7.6.5 Middle East and Africa
                 7.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2018 to 2026
                     7.7.1 North America
                         7.7.1.1 North America market estimates and forecast, 2014 - 2026 (USD Million)
                         7.7.1.2 U.S.
                             7.7.1.2.1 U.S. TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.1.3 Canada
                             7.7.1.3.1 Canada TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                     7.7.2 Europe
                         7.7.2.1 Europe TNF Inhibitor Drugs market, 2014 - 2026 (USD Million)
                         7.7.2.2 U.K.
                             7.7.2.2.1 U.K. TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.2.3 Germany
                             7.7.2.3.1 Germany TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.2.4 Spain
                             7.7.2.4.1 Spain TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.2.5 France
                             7.7.2.5.1 France TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.2.6 Italy
                             7.7.2.6.1 Italy TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                     7.7.3 Asia Pacific
                         7.7.3.1 Asia Pacific TNF Inhibitor Drugs market, 2014 - 2026 (USD Million)
                         7.7.3.2 Japan
                             7.7.3.2.1 Japan TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.3.3 China
                             7.7.3.3.1 China TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.3.4 India
                             7.7.3.4.1 India TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.3.5 South Korea
                             7.7.3.5.1 South Korea TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.3.6 Australia
                             7.7.3.6.1 Australia TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                     7.7.4 Latin America
                     7.7.5 Latin America TNF Inhibitor Drugs market, 2014 - 2026 (USD Million)
                         7.7.5.1 Brazil
                             7.7.5.1.1 Brazil TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.5.2 Mexico
                             7.7.5.2.1 Mexico TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.5.3 Argentina
                             7.7.5.3.1 Argentina TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                     7.7.6 MEA
                         7.7.6.1 MEA TNF Inhibitor Drugs market, 2014 - 2026 (USD Million)
                         7.7.6.2 South Africa
                             7.7.6.2.1 South Africa TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.6.3 Saudi Arabia
                             7.7.6.3.1 Saudi Arabia TNF inhibitor drugs market, 2014 - 2026 (USD Million)
                         7.7.6.4 UAE
                             7.7.6.4.1 UAE TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Chapter 8 TNF Inhibitor Drugs market - Competitive Analysis
                 8.1 Recent Developments & Impact Analysis, by Key Market Participants
                     8.1.1 Ansoff matrix
                     8.1.2 Heat map analysis
                 8.2 Company Categorization
                     8.2.1 Innovators
                     8.2.2 Market Leaders
                 8.3 Vendor Landscape
                     8.3.1 List of key distributors and channel partners
                     8.3.2 Key customers
                     8.3.3 Key company market share analysis, 2018
                 8.4 Public Companies
                     8.4.1 Company market position analysis
                     8.4.2 Company Market Share, by region
                     8.4.3 Competitive Dashboard Analysis
                 8.5 Private Companies
                     8.5.1 List of key emerging companies
                     8.5.3 Regional network map
                     8.5.4 Company market position analysis
                 8.6 Supplier Ranking
                 8.7 Company Profiles
                     8.7.1 AbbVie, Inc.
                         8.7.1.1 Company overview
                         8.7.1.2 Financial performance
                         8.7.1.3 Product benchmarking
                         8.7.1.4 Strategic initiatives
                     8.7.2 Amgen, Inc.
                         8.7.2.1 Company overview
                         8.7.2.2 Financial performance
                         8.7.2.3 Product benchmarking
                         8.7.2.4 Strategic initiatives
                     8.7.3 Johnson & Johnson Services, Inc.
                         8.7.3.1 Company overview
                         8.7.3.2 Financial performance
                         8.7.3.3 Product benchmarking
                         8.7.3.4 Strategic initiatives
                     8.7.4 UCB S.A.
                         8.7.4.1 Company overview
                         8.7.4.2 Financial performance
                         8.7.4.3 Product benchmarking
                         8.7.4.4 Strategic initiatives
                     8.7.5 Pfizer, Inc.
                         8.7.5.1 Company overview
                         8.7.5.2 Financial performance
                         8.7.5.3 Product benchmarking
                         8.7.5.4 Strategic initiatives
                     8.7.6 Novartis International AG
                         8.7.6.1 Company overview
                         8.7.6.2 Financial performance
                         8.7.6.3 Product benchmarking
                         8.7.6.4 Strategic initiatives
                     8.7.7 Boehringer Ingelheim Pharmaceuticals, Inc.
                         8.7.7.1 Company overview
                         8.7.7.2 Financial performance
                         8.7.7.3 Product benchmarking
                         8.7.7.4 Strategic initiatives
                     8.7.8 Merck & Co., Inc.
                         8.7.8.1 Company overview
                         8.7.8.2 Product benchmarking
                         8.7.8.3 Strategic initiatives
Chapter 9 Recommendations

List of Tables

Table 1 Primary interview details: North America
Table 2 Primary interview details: Europe
Table 3 Primary interview details: Asia Pacific
Table 4 Primary interview details: Middle East and Africa
Table 5 List of secondary sources
Table 6 List of abbreviations
Table 7 Product pipeline
Table 8 Regulatory framework
Table 9 North America TNF inhibitor drugs market, by country, 2014 - 2026 (USD Million)
Table 10 North America TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 11 North America TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 12 North America TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 13 U.S. TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 14 U.S. TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 15 U.S. TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 16 Canada TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 17 Canada TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 18 Canada TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 19 Europe TNF inhibitor drugs market, by country, 2014 - 2026 (USD Million)
Table 20 Europe TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 21 Europe TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 22 Europe TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 23 U.K. TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 24 U.K. TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 25 U.K. TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 26 Germany TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 27 Germany TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 28 Germany TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 29 Spain TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 30 Spain TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 31 Spain TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 32 France TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 33 France TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 34 France TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 35 Italy TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 36 Italy TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 37 Italy TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 38 Asia Pacific TNF inhibitor drugs market, by country, 2014 - 2026 (USD Million)
Table 39 Asia Pacific TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 40 Asia Pacific TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 41 Asia Pacific TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 42 Japan TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 43 Japan TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 44 Japan TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 45 China TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 46 China TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 47 China TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 48 India TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 49 India TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 50 India TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 51 South Korea TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 52 South Korea TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 53 South Korea TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 54 Australia TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 55 Australia TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 56 Australia TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 57 Latin America TNF inhibitor drugs market, by country, 2014 - 2026 (USD Million)
Table 58 Latin America TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 59 Latin America TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 60 Latin America TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 61 Brazil TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 62 Brazil TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 63 Brazil TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 64 Mexico TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 65 Mexico TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 66 Mexico TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 67 Argentina TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 68 Argentina TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 69 Argentina TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 70 MEA TNF inhibitor drugs market, by country, 2014 - 2026 (USD Million)
Table 71 MEA TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 72 MEA TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 73 MEA TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 74 South Africa TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 75 South Africa TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 76 South Africa TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 77 Saudi Arabia TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 78 Saudi Arabia TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 79 Saudi Arabia TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)
Table 80 UAE TNF inhibitor drugs market, by product, 2014 - 2026 (USD Million)
Table 81 UAE TNF inhibitor drugs market, by application, 2014 - 2026 (USD Million)
Table 82 UAE TNF inhibitor drugs market, by sales channel, 2014 - 2026 (USD Million)

List of Figures

Fig. 1 TNF inhibitor drugs market market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Primary interviews in North America
Fig. 6 Primary interviews in Europe
Fig. 7 Primary interviews in Asia Pacific
Fig. 8 Primary interviews in Middle East and Africa
Fig. 9 Market research sales channels
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Market outlook (2018)
Fig. 14 Segment Outlook (Product, 2018)
Fig. 15 Strategy framework
Fig. 16 Penetration & growth prospect mapping
Fig. 17 Consumer behavior analysis
Fig. 18 Market driver relevance analysis (Current & future impact)
Fig. 19 Market restraint relevance analysis (Current & future impact)
Fig. 20 Porter's five forces analysis
Fig. 21 PESTLE analysis
Fig. 22 Strategy mapping
Fig. 23 TNF inhibitor drugs market: Product movement analysis
Fig. 24 Product segment dashboard
Fig. 25 TNF inhibitor drugs market product outlook: Key takeaways
Fig. 26 Humira market, 2014 - 2026 (USD Million)
Fig. 27 Enbrel market, 2014 - 2026 (USD Million)
Fig. 28 Remicade market, 2014 - 2026 (USD Million)
Fig. 29 Simponi/Simponi Aria market, 2014 - 2026 (USD Million)
Fig. 30 Cimzia, 2014 - 2026 (USD Million)
Fig. 31 Biosimilars market, 2014 - 2026 (USD Million)
Fig. 32 TNF inhibitor drugs market: Application movement analysis
Fig. 33 Application segment dashboard
Fig. 34 TNF inhibitor drugs market application outlook: Key takeaways
Fig. 35 Rheumatoid arthritis market, 2014 - 2026 (USD Million)
Fig. 36 Psoriasis market, 2014 - 2026 (USD Million)
Fig. 37 Psoriatic arthritis market, 2014 - 2026 (USD Million)
Fig. 38 Crohn's disease market, 2014 - 2026 (USD Million)
Fig. 39 Ulcerative colitis market, 2014 - 2026 (USD Million)
Fig. 40 Ankylosing spondylitis market, 2014 - 2026 (USD Million)
Fig. 41 Juvenile idiopathic arthritis market, 2014 - 2026 (USD Million)
Fig. 42 Hidradenitis suppurativa market, 2014 - 2026 (USD Million)
Fig. 43 Others market, 2014 - 2026 (USD Million)
Fig. 44 TNF inhibitor drugs market: Sales channel movement analysis
Fig. 45 Sales channel segment dashboard
Fig. 46 TNF inhibitor drugs market sales channel outlook: Key takeaways
Fig. 47 Hospital pharmacy market, 2014 - 2026 (USD Million)
Fig. 48 Specialty pharmacy market, 2014 - 2026 (USD Million)
Fig. 49 Online pharmacy market, 2014 - 2026 (USD Million)
Fig. 50 Regional outlook, 2018 & 2026
Fig. 51 Regional market dashboard
Fig. 52 Regional market place: Key takeaways
Fig. 53 North America market share and leading players (2018)
Fig. 54 Europe market share and leading players (2018)
Fig. 55 Asia Pacific market share and leading players (2018)
Fig. 56 Latin America market share and leading players (2018)
Fig. 57 Middle East and Africa market share and leading players (2018)
Fig. 58 North America, SWOT
Fig. 59 Europe, SWOT
Fig. 60 Asia Pacific, SWOT
Fig. 61 Latin America, SWOT
Fig. 62 Middle East and Africa, SWOT
Fig. 63 North America
Fig. 64 North America TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 65 U.S.
Fig. 66 U.S. TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 67 Canada
Fig. 68 Canada TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 69 Europe
Fig. 70 Europe TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 71 U.K..
Fig. 72 U.K. TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 73 Germany
Fig. 74 Germany TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 75 Spain
Fig. 76 Spain TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 77 France
Fig. 78 France TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 79 Italy
Fig. 80 Italy TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 81 Asia Pacific
Fig. 82 Asia Pacific TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 83 Japan
Fig. 84 Japan TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 85 China
Fig. 86 China TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 87 India
Fig. 88 India TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 89 South Korea
Fig. 90 South Korea TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 91 Australia
Fig. 92 Australia TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 93 Latin America
Fig. 94 Latin America TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 95 Brazil
Fig. 96 Brazil TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 97 Mexico
Fig. 98 Mexico TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 99 Argentina
Fig. 100 Argentina TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 101 Middle East and Africa
Fig. 102 MEA TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 103 South Africa
Fig. 104 South Africa TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 105 Saudi Arabia
Fig. 106 Saudi Arabia TNF inhibitor drugs market, 2014 - 2026 (USD Million)
Fig. 107 UAE
Fig. 108 UAE TNF inhibitor market, 2014 - 2026 (USD Million)
Fig. 109 Ansoff Matrix
Fig. 110 Heat map analysis
Fig. 111 Company market share analysis
Fig. 112 Company market position analysis
Fig. 113 Company market share, by region
Fig. 114 Market differentiators
Fig. 115 Regional network map